Avalo TherapeuticsAVTX -3.71%23 Return-on-Tangible-Asset is -80.39% as of Mar. 2026. GuruFocus rates AVTX with a GF Score™ of 23/100 and a GF Value™ of $0.03 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 1,413 Biotechnology companies, Avalo Therapeutics ranks worse than 72.47% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Avalo Therapeutics's annualizedNet Income for the quarter that ended in Mar. 2026 was $-78.52 Mil. Avalo Therapeutics's average total tangible assets for the quarter that ended in Mar. 2026 was $97.67 Mil. Therefore, Avalo Therapeutics's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was -80.39%.
The historical rank and industry rank for Avalo Therapeutics's Return-on-Tangible-Asset or its related term are showing as below:
AVTX'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -270.01 Med: -109.23 Max: 142.85
Current: -76.47
During the past 13 years, Avalo Therapeutics's highest Return-on-Tangible-Asset was 142.85%. The lowest was -270.01%. And the median was -109.23%.
AVTX's Return-on-Tangible-Asset is ranked worse than 72.47% of 1413
companies
in the Biotechnology industry
Industry Median: -35.77
vs AVTX: -76.47
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Avalo Therapeutics Return-on-Tangible-Asset Related Terms
Avalo Therapeutics Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Avalo Therapeutics's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AVTX vs SANA, ANRO, REPL: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Avalo Therapeutics's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avalo Therapeutics Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Avalo Therapeutics's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Avalo Therapeutics's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of -80.39% mean?
Avalo Therapeutics (AVTX) has a Return-on-Tangible-Asset of -80.39% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Avalo Therapeutics and its competitors. According to the industry distribution chart, Avalo Therapeutics ranks #1024 out of 1413 companies in the Biotechnology industry, placing it in the top 72.5%.
Is Avalo Therapeutics' Return-on-Tangible-Asset too high?
Avalo Therapeutics' current Return-on-Tangible-Asset is -80.39%. Based on the distribution chart, Avalo Therapeutics ranks #1024 out of 1413 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Avalo Therapeutics has a GF Score™ of 23/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Avalo Therapeutics' Return-on-Tangible-Asset compare to SANA and ANRO?
According to the Biotechnology industry distribution chart, Avalo Therapeutics ranks #1024 out of 1413 companies for Return-on-Tangible-Asset. This places Avalo Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Avalo Therapeutics and its competitors. Avalo Therapeutics's current Return-on-Tangible-Asset is -80.39%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avalo Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Avalo Therapeutics (AVTX) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.03, compared to a current price of $19.18 — trading 63833.3% above its estimated fair value. The current Return-on-Tangible-Asset is -80.39%. Avalo Therapeutics' overall GF Score™ is 23/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Avalo Therapeutics (AVTX), the current Return-on-Tangible-Asset is -80.39% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Avalo Therapeutics (AVTX) Overvalued in 2026?
Based on GuruFocus' analysis, Avalo Therapeutics stock appears to be overvalued.
The current stock price of $19.18 is trading 63833.3% above its estimated GF Value™ of $0.03.
GuruFocus considers Avalo Therapeutics to be Significantly Overvalued.
Key valuation signals for AVTX:
Return-on-Tangible-Asset: -80.39%
GF Value™: $0.03 vs. price of $19.18 (63833.3% above fair value)
No single metric tells the full story. See the AVTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
23GF Score
Get the complete analysis for AVTX
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AVTX has been successfully added to your 
